June 14, 6:56 AM
Truist Securities analyst Bill Chappell initiates coverage on Oatly Group (NASDAQ:OTLY) with a Buy rating and announces Price Target of $35.
June 14, 6:54 AM
Guggenheim analyst Laurent Grandet initiates coverage on Oatly Group (NASDAQ:OTLY) with a Buy rating and announces Price Target of $32.
June 14, 6:53 AM
Citigroup analyst Yigal Nochomovitz upgrades CRISPR Therapeutics (NASDAQ:CRSP) from Sell to Neutral and raises the price target from $55 to $132.
June 14, 6:50 AM
Telsey Advisory Group analyst Dana Telsey maintains Vintage Wine Estates (NASDAQ:VWE) with a Outperform and raises the price target from $15 to $16.
June 14, 6:49 AM
Raymond James analyst Justin Jenkins upgrades EnLink Midstream (NYSE:ENLC) from Market Perform to Outperform and announces $7.5 price target.
Long-awaited Novavax’s COVID-19 Vaccine Results Hit 90% Efficacy In Pivotal US Trial, 100% Efficacy Against Moderate, Severe Infection
June 14, 6:44 AM
Novavax Inc (NASDAQ:NVAX) has finally completed its U.S. Phase 3 trial for its protein-based COVID-19 vaccine candidate. Overall efficacy in the…
June 14, 6:35 AM
SVB Leerink analyst Geoffrey Porges maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Market Perform and lowers the price target from $250 to $200.
BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference and the International Conference on Phage Therapy and Bacteriophages
June 14, 6:30 AM
BiomX Inc. (NYSE:PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today